Kinase News and Research

RSS

Pharmacyclics total revenue for fourth quarter 2013 increases 113% to $123.6 million

Pharmacyclics, Inc. today reported financial results and recent developments for the quarter and year ended December 31, 2013.

20 Feb 2014

Lung cancer patients with Del19 mutation benefit most from afatinib

Afatinib has been approved in Germany since September 2013 for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with activating EGF receptor mutations who have not been treated with an EGF receptor tyrosine-kinase inhibitor (EGFR TKI).

20 Feb 2014

Purdue’s new innovation improves drug therapies by making real-time decisions about treatment options

Oncologists and cancer patients could improve the results of drug therapies by making real-time decisions about treatment options using an innovation developed in Purdue University's College of Pharmacy.

20 Feb 2014

PBL Assay Science, HumanZyme ink licensing agreement to expand reagent offerings

PBL Assay Science announces a licensing agreement with HumanZyme, Inc. (Chicago, USA) to expand reagent offerings. The agreement allows PBL to provide ~50 authentic human cell-expressed (HCE) cytokines and growth factors directly to scientists worldwide.

From PBL Assay Science 20 Feb 2014

Driver mutations found in more than half of adenosquamous lung carcinomas

Analysis of a large cohort of Chinese patients with adenosquamous lung carcinoma has identified known mutant kinases in more than half of the tumours, researchers report in the Journal of Thoracic Oncology.

19 Feb 2014

Experimental drug dinaciclib may improve myeloid leukemia, myeloma therapies

A pre-clinical study led by Virginia Commonwealth University Massey Cancer Center and Department of Internal Medicine researchers suggests that an experimental drug known as dinaciclib could improve the effectiveness of certain multiple myeloma and myeloid leukemia therapies.

19 Feb 2014

IGF1R linked to mutation-negative lung cancer erlotinib resistance

Activation of the insulin-like growth factor 1 receptor plays a key role in acquired resistance to erlotinib in lung cancer with wild-type epidermal growth factor receptor, research suggests.

18 Feb 2014

New therapeutic target may help repair muscle damage

Researchers at the Stanford University School of Medicine have pinpointed why normal aging is accompanied by a diminished ability to regain strength and mobility after muscle injury: Over time, stem cells within muscle tissues dedicated to repairing damage become less able to generate new muscle fibers and struggle to self-renew.

18 Feb 2014

Afatinib ‘first line’ for advanced mutation-positive lung cancer

Afatinib should be given as a first-line treatment for Asian patients with advanced, epidermal growth factor receptor mutation-positive, non-small-cell lung cancer, researchers recommend.

17 Feb 2014

Valproic acid metabolism and obesity: an interview with Dr. Namandjé Bumpus, Johns Hopkins Medicine

Valproic acid is one of the most widely prescribed drugs for the treatment of epilepsy. It has also been shown to be effective for the treatment of mood disorders and migraine headaches.

17 Feb 2014

FDA grants full approval of SYNRIBO for injection

Teva Pharmaceutical Industries Ltd. today announced that the U.S. Food and Drug Administration has granted full approval of SYNRIBO (omacetaxine mepesuccinate) for injection. This oncology portfolio product received an accelerated approval in October, 2012 with additional clinical trial data required to fulfill post marketing requirements set forth by the FDA.

13 Feb 2014

Long-term physical activity improves cardiovascular health by targeting heart cells' powerhouses

Whether lifting weights in a gym or just walking around the block, exercise has many benefits, such as helping people lose weight and build stronger muscles. Some studies suggest that it may reduce the risk of developing cancer and other diseases.

13 Feb 2014

Combination of SYK and FLT3 enzymes promotes progression of acute myelogenous leukemia

Reinforcing the need to look beyond genomic alterations to understand the complexity of cancer, researchers from Dana-Farber/Boston Children's Cancer and Blood Disorders Center report that a normal enzyme called SYK pairs with FLT3, the most commonly mutated enzyme found in acute myelogenous leukemia (AML), to promote progression of the disease.

11 Feb 2014

Two oncogenes work together to sustain population of cells in lung squamous cell carcinoma

Patients with a common form of lung cancer — lung squamous cell carcinoma — have very few treatment options. That situation may soon change.

10 Feb 2014

Researchers find biological weakness in the workings of mutated gene involved in human cancers

NYU Langone Medical Center researchers have found a biological weakness in the workings of the most commonly mutated gene involved in human cancers, known as mutant K-Ras, which they say can be exploited by drug chemotherapies to thwart tumor growth.

10 Feb 2014

Researchers discover genetic mutations that cause deadly lung disease

A team of researchers, led by physicians and scientists at Intermountain Medical Center and ARUP Laboratories in Salt Lake City, has made a medical breakthrough by discovering genetic mutations that cause a rare and deadly lung disease.

4 Feb 2014

New molecule could help lower diabetic patients' risk of developing dementia or Alzheimer's

Researchers at the Hebrew university of Jerusalem have created a molecule that could potentially lower diabetic patients' higher risk of developing dementia or Alzheimer's disease.

30 Jan 2014

TCGA Research Network identify new potential therapeutic targets for major form of bladder cancer

Investigators with The Cancer Genome Atlas (TCGA) Research Network have identified new potential therapeutic targets for a major form of bladder cancer, including important genes and pathways that are disrupted in the disease.

30 Jan 2014

Findings on molecular defects behind bladder cancer may pave way for new, targeted treatments

The once sketchy landscape of the molecular defects behind bladder cancer now resembles a road map to new, targeted treatments thanks to the unified efforts of scientists and physicians at 40 institutions.

30 Jan 2014

Scientists develop monoclonal antibodies that may lead to new, innovative treatments for cancer patients

Using monoclonal antibodies to fight cancer is a complex, yet promising area of study. At Memorial Sloan Kettering Cancer Center, physician-scientists have focused their attention on expanding the current therapeutic antibody repertoire, and believe a newly developed platform will do just that - ultimately leading to new and innovative treatments for cancer patients with a broad range of malignancies.

29 Jan 2014

Kinase News and Research

Pharmacyclics total revenue for fourth quarter 2013 increases 113% to $123.6 million

Lung cancer patients with Del19 mutation benefit most from afatinib

Purdue’s new innovation improves drug therapies by making real-time decisions about treatment options

PBL Assay Science, HumanZyme ink licensing agreement to expand reagent offerings

Driver mutations found in more than half of adenosquamous lung carcinomas

Experimental drug dinaciclib may improve myeloid leukemia, myeloma therapies

IGF1R linked to mutation-negative lung cancer erlotinib resistance

New therapeutic target may help repair muscle damage

Afatinib ‘first line’ for advanced mutation-positive lung cancer

Valproic acid metabolism and obesity: an interview with Dr. Namandjé Bumpus, Johns Hopkins Medicine

FDA grants full approval of SYNRIBO for injection

Long-term physical activity improves cardiovascular health by targeting heart cells' powerhouses

Combination of SYK and FLT3 enzymes promotes progression of acute myelogenous leukemia

Two oncogenes work together to sustain population of cells in lung squamous cell carcinoma

Researchers find biological weakness in the workings of mutated gene involved in human cancers

Researchers discover genetic mutations that cause deadly lung disease

New molecule could help lower diabetic patients' risk of developing dementia or Alzheimer's

TCGA Research Network identify new potential therapeutic targets for major form of bladder cancer

Findings on molecular defects behind bladder cancer may pave way for new, targeted treatments

Scientists develop monoclonal antibodies that may lead to new, innovative treatments for cancer patients

Measuring Drug-Target Residence Times with Biochemical Assays eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News